Repotrectinib Approvals Expand to Include Patients with NTRK+ Solid Tumors
Read time: 1 minute On June 13, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of repotrectinib (Augtyro™) to treat patients with advanced NTRK